Detailed explanation of the dosage and administration of tepotinib: how to adjust the dosage regimen

The standard recommended dose of Tepotinib for the treatment of non-small cell lung cancer (NSCLC) is usually 450 mg orally once daily, with or without food. This fixed-dose design helps patients adhere to long-term treatment and reduces compliance issues caused by daily dose changes. Its efficacy is based on maintaining a stable blood drug concentration, so the drug should be taken as regularly as possible and should not be discontinued on its own. This dose is based on the effective and safe range summarized in multiple foreign clinical trials, taking into account both efficacy and side effect management.

However, in actual clinical use, due to individual differences, the dosage regimen of tepotinib may need to be appropriately adjusted based on patient tolerance. If the patient experiences intolerable adverse reactions during treatment, such as moderate to severe edema, diarrhea, nausea, fatigue, or abnormal liver function, the doctor may choose to temporarily discontinue the medication, reduce the dose, or extend the medication interval. Common adjustments include reducing the dose from 450 mg per day to 225 mg per day, and then returning to the standard dose as appropriate after symptoms subside. Such individualized adjustment principles must be carried out under the guidance of professional physicians to prevent patients from changing the dose without authorization, which may lead to a decrease in efficacy or an increase in toxicity.

In addition, in some patients with other diseases or taking hepatic enzyme inducers or inhibitors, possible interactions between drugs should be evaluated, and dose adaptation or monitoring should be performed if necessary. Patients with hepatic insufficiency are the key group of people to pay attention to when using tepotinib. Once there is obvious elevation of transaminases or abnormal bilirubin, priority should be given to drug correlation and adjustments should be made accordingly. Pregnant or lactating women are not recommended to use this product, and women of childbearing age should take contraceptive measures.

In general, the standard dosage regimen of tepotinib focuses on simplicity and safety, and also has the possibility of flexible adjustment to cope with adverse reactions or specific pathophysiological conditions.

Reference materials:https://www.tepotinib.com/